Patents Represented by Attorney, Agent or Law Firm James E. Klaniecki
  • Methods of use of the TACI/TACI-L interaction
    Patent number: 8133976
    Abstract: The invention discloses a novel interaction between a TNF receptor (TACI) and its interacting ligand (TACI-L). Also disclosed are methods of screening candidate molecules to determine potential antagonists and agonists of the TACI/TACI-L interaction. The use of the antagonists and agonists as therapeutics to treat autoimmune diseases, inflammation, and to inhibit graft vs. host rejections is further disclosed.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: March 13, 2012
    Assignee: Immunex Corporation
    Inventors: Raymond G. Goodwin, Wanwan S. Din
  • Methods of antagonizing LDCAM and CRTAM
    Patent number: 8043615
    Abstract: The invention pertains to agonists and antagonists of LDCAM and methods of treating disease and infection by administering one or more LDCAM antagonists or agonists.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: October 25, 2011
    Assignee: Amgen Inc.
    Inventors: Laurent J. Galibert, Wei Yan
  • Metalloproteinase inhibitor
    Patent number: 7994136
    Abstract: A novel metalloproteinase inhibitor, analogs thereof, polynucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders caused by excessive amounts of metalloproteinase are also disclosed.
    Type: Grant
    Filed: May 19, 1989
    Date of Patent: August 9, 2011
    Assignee: Amgen Inc.
    Inventors: Keith E. Langley, Yves A. DeClerck, Thomas C. Boone
  • IL-17 receptor like molecules and uses thereof
    Patent number: 7943738
    Abstract: The present invention provides for IL-17 receptor like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, agonists and antagonists (including selective binding agents), and methods for producing IL-17 receptor like polypeptides. Also provided for are methods for treatment, diagnosis, amelioration, or prevention of diseases with IL-17 receptor like polypeptides.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: May 17, 2011
    Assignee: Amgen Inc.
    Inventors: Eugene Medlock, Richard Yeh, Scott Michael Sibiger, Gary S. Elliott, Hung Q. Nquyen, Shuqian Jing
  • Antibodies that bind B7L-1
    Patent number: 7939640
    Abstract: The invention is directed to B7L-1 as a purified and isolated protein, the DNA encoding the B7L-1, host cells transfected with cDNAs encoding B7L-1 and processes for preparing B7L-1 polypeptides.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: May 10, 2011
    Assignee: Immunex Corporation
    Inventor: Peter Robert Baum
  • IL-17 receptor A antigen binding proteins
    Patent number: 7939070
    Abstract: The present invention relates to IL-17 Receptor A antigen binding proteins, such as antibodies, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: May 10, 2011
    Assignee: Amgen Inc.
    Inventors: Joel Tocker, Jacques J. Peschon, James F. Smothers
  • Chordin-like molecules and uses thereof
    Patent number: 7842784
    Abstract: The present invention provides Chordin-Like (CHL) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing CHL polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with CHL polypeptides.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: November 30, 2010
    Assignee: Amgen Inc.
    Inventors: Naoki Nakayama, Duanzhi Wen, Chun-ya Han, Ching He, Dongyin Yu
  • Methods of treating psoriasis using IL-17 Receptor A antibodies
    Patent number: 7833527
    Abstract: The present invention relates to IL-17 Receptor A antigen binding proteins, such as antibodies, and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation.
    Type: Grant
    Filed: September 27, 2007
    Date of Patent: November 16, 2010
    Assignee: Amgen Inc.
    Inventors: Joel Tocker, Jacques J. Peschon, David Fitzpatrick
  • Polynucleotides encoding IL-17 receptor A antigen binding proteins
    Patent number: 7786284
    Abstract: The present invention relates to IL-17 receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, and the polynucleotide sequences encoding them, as well as host cells, expression vectors, and methods of making IL-17 receptor A antigen binding proteins.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: August 31, 2010
    Assignee: Amgen Inc.
    Inventors: Joel Tocker, Jacques J. Peschon, James F. Smothers
  • Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
    Patent number: 7767206
    Abstract: The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and the antigen binding proteins, such as antibodies, that bind thereto and inhibit IL-17 ligand family members from binding to and activating IL-17 Receptor A or a receptor complex comprising IL-17 Receptor A.
    Type: Grant
    Filed: September 27, 2007
    Date of Patent: August 3, 2010
    Assignee: Amgen Inc.
    Inventors: Joel Tocker, Christopher Mehlin, Ai Ching Lim
  • Antibodies that bind LDCAM
    Patent number: 7741115
    Abstract: The invention is directed to LDCAM as a purified and isolated protein, the DNA encoding the LDCAM, host cells transfected with cDNAs encoding LDCAM, processes for preparing LDCAM polypeptides and compositions and methods for treating utilizing LDCAM polypeptides.
    Type: Grant
    Filed: July 16, 2008
    Date of Patent: June 22, 2010
    Assignee: Immunex Corporation
    Inventors: Peter Robert Baum, William Christian Fanslow, III
  • Polynucleotides encoding molecules designated LDCAM
    Patent number: 7659385
    Abstract: The invention is directed to LDCAM as a purified and isolated protein, the DNA encoding the LDCAM, host cells transfected with cDNAs encoding LDCAM, processes for preparing LDCAM polypeptides and compositions and methods for treating utilizing LDCAM polypeptides.
    Type: Grant
    Filed: July 14, 2008
    Date of Patent: February 9, 2010
    Assignee: Immunex Corporation
    Inventors: Peter Robert Baum, William Christian Fanslow, III
  • IL-receptor like molecules and uses thereof
    Patent number: 7611857
    Abstract: The present invention provides for IL-17 receptor like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, agonists and antagonists (including selective binding agents), and methods for producing IL-17 receptor like polypeptides. Also provided for are methods for treatment, diagnosis, amelioration, or prevention of diseases with IL-17 receptor like polypeptides.
    Type: Grant
    Filed: October 11, 2005
    Date of Patent: November 3, 2009
    Assignee: Amgen Inc.
    Inventors: Eugene Medlock, Richard Yeh, Scott Michael Silbiger, Gary S. Elliott, Hung Q. Nquyen, Shuqian Jing
  • Chordin-like molecules and uses thereof
    Patent number: 7482324
    Abstract: The present invention provides Chordin-Like (CHL) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing CHL polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with CHL polypeptides.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: January 27, 2009
    Assignee: Amgen Inc.
    Inventors: Naoki Nakayama, Duanzhi Wen, Chun-ya Han, Ching He, Dongyin Yu
  • Chordin-like molecules and uses thereof
    Patent number: 7459291
    Abstract: The present invention provides Chordin-Like, (CHL) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing CHL polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with CHL polypeptides.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: December 2, 2008
    Assignee: Amgen Inc.
    Inventors: Naoki Nakayama, Duanzhi Wen, Chun-ya Han, Ching He, Dongyin Yu
  • Methods of treating asthma by administering interleukin-17 receptor
    Patent number: 7432237
    Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: October 7, 2008
    Assignee: Immunex Corporation
    Inventors: Zhengbin Yao, Melanie K. Spriggs, William C. Fanslow
  • Molecules designated LDCAM
    Patent number: 7402655
    Abstract: The invention is directed to LDCAM as a purified and isolated protein, the DNA encoding the LDCAM, host cells transfected with cDNAs encoding LDCAM, processes for preparing LDCAM polypeptides and compositions and methods for treating utilizing LDCAM polypeptides.
    Type: Grant
    Filed: February 6, 2001
    Date of Patent: July 22, 2008
    Assignee: Immunex Corporation
    Inventors: Peter Robert Baum, William Christian Fanslow, III
  • Methods of treating osteoarthritis using IL-17 receptor proteins in combination with TNF-receptor proteins
    Patent number: 7338930
    Abstract: Methods for regulating levels of nitric oxide are disclosed. The methods utilize IL-17 receptors, which may be used in conjunction with inhibitor of IL-1 and/or TNF.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: March 4, 2008
    Assignee: Immunex Corporation
    Inventor: Anthony B. Troutt
  • Methods of using flt3-ligand in hematopoietic cell transplantation
    Patent number: 7294331
    Abstract: Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to Flt3-ligand as an isolated protein, the DNA encoding the Flt3-ligand, host cells transfected with cDNAs encoding Flt3-ligand, compositions comprising Flt3-ligand and methods of using Flt3-ligand in hematopoietic cell transplantation.
    Type: Grant
    Filed: December 5, 2002
    Date of Patent: November 13, 2007
    Assignee: Immunex Corporation
    Inventors: Stewart D. Lyman, M. Patricia Beckmann
  • Methods of treating allergy by administering interleukin-17 receptor
    Patent number: 7273843
    Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: September 25, 2007
    Assignee: Immunex Corporation
    Inventors: Zhengbin Yao, Melanie K. Spriggs, William C. Fanslow